Among these, the TB reactivation risk should be assessed in all patients, and in case of positive results, non-anti-TNF-α-targeted biologics for RA, UTK, or SCK for PsA, and SCK for AS represent the safest option. The gene discussed is TNF; the disease is rheumatoid arthritis.